Introduction {#tca13298-sec-0005}
============

Lung cancer is the most common cause of cancer‐related death among all human cancers. It is estimated that there are 571 340 men and women living in the United States with a history of lung cancer, and the number of estimated new cases with lung cancer will be 228 150 in 2019.[1](#tca13298-bib-0001){ref-type="ref"} Compared with histological classification, genes play an increasingly important role in the diagnosis, treatment, and prognosis of non‐small cell lung cancer (NSCLC). The mutations of targeted driver genes *EGFR*, *BRAF* and *HER2*, or the rearrangements of *ALK* or *ROS1* only exist in less than half of lung adenocarcinoma cases, but in other cases of NSCLC without targeted molecular abnormalities the only therapeutic option is conventional platinum‐based doublet therapy maintenance for nonsquamous NSCLC.[2](#tca13298-bib-0002){ref-type="ref"}, [3](#tca13298-bib-0003){ref-type="ref"} Despite the fact that great progress has been made in chemotherapy, radiation therapy, surgery, and immunotherapy in lung cancer, the five‐year survival rates for NSCLC are only 23%.[1](#tca13298-bib-0001){ref-type="ref"} Since the precise molecular mechanisms of NSCLC remains unknown, it is extremely important to investigate molecular mechanisms and to develop effective therapeutic strategies in NSCLC.

With the rapid development of bioinformatics such as microarray technology, some high throughput platforms for analysis of gene expression are commonly used to find the differentially expressed genes (DEGs) during tumorigenesis.[4](#tca13298-bib-0004){ref-type="ref"} Now, through gene expression profiling studies using microarray technology, more and more DEGs associated with NSCLC have been identified. However, the DEGs identified with microarray technology depend on the sample size, tumor TMN, gender, ethnic group and other factors. A better option might be for DEGs to be obtained from different microarrays.

In this study, four microarray datasets (GSE18842,[5](#tca13298-bib-0005){ref-type="ref"} GSE33532,[6](#tca13298-bib-0006){ref-type="ref"} GSE62113,[7](#tca13298-bib-0007){ref-type="ref"} and GSE74706[8](#tca13298-bib-0008){ref-type="ref"}) were downloaded from the GEO database, and key genes identified by combining bioinformatics analyses in NSCLC. Gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with NSCLC were investigated, and the key genes associated with NSCLC were identified by network construction. Subsequently, we validated the expression of key genes related to NSCLC. Furthermore, we investigated the potential candidate biomarkers for their utility in diagnosis, prognosis, and drug targeting in NSCLC.

Methods {#tca13298-sec-0006}
=======

Gene expression profile data {#tca13298-sec-0007}
----------------------------

In this study, four gene expression profiles (GSE18842, GSE33532, GSE62113 and GSE74706) were downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>). GSE18842 included 46 NSCLC tissue samples and 45 paired nontumor samples. GSE33532 consisted of four different sites (A, B, C, D) of individual primary tumors and matched distant normal lung tissue from 20 patients. GSE62113 was total RNAs from xenografts, primary tumor, and normal adjacent tissues. GSE74706 included 18 NSCLC tissue samples and 18 paired nontumor samples. All the datasets included met the following criteria: (i) the tissue samples were gathered from NSCLC patients and corresponding adjacent or normal tissues; (ii) the tissue samples were tested by authority agency that recognized by Food and Drug Administration (FDA); (iii) a total of 15 samples or more were included; (iv) all the studies chosen had been previously published in the English language.

Data preprocessing and identification of DEGs {#tca13298-sec-0008}
---------------------------------------------

GEO2R is an interactive web tool used to compare two groups of samples and is capable of analyzing most of the GEO series.[9](#tca13298-bib-0009){ref-type="ref"} In this study, GEO2R was used to find DEGs between lung cancer and normal tissue samples. The cutoff criteria were adjusted *P*‐value (adj. *P*) \<0.05 and \|logFC\| ≥2. FunRich, a stand‐alone software tool used mainly for functional enrichment and interaction network analysis of genes and proteins,[10](#tca13298-bib-0010){ref-type="ref"} was used to plot Venn diagrams from four datasets.

Functional and pathway enrichment analysis {#tca13298-sec-0009}
------------------------------------------

The GO (<http://www.geneontology.org>) database mainly includes three categories: biological process (BP), cellular component (CC), and molecular function (MF).[11](#tca13298-bib-0011){ref-type="ref"} The KEGG (<http://www.genome.ad.jp/kegg/>) database collects genomic, chemical, and systematic functional information.[12](#tca13298-bib-0012){ref-type="ref"} The ClusterProfiler package implements methods to analyze and visualize functional profiles of gene and gene clusters.[13](#tca13298-bib-0013){ref-type="ref"} In this study, GO terms and KEGG pathways were analyzed using the ClusterProfiler package with the enrichment threshold of *P* \< 0.05.

PPI network construction and analysis of modules {#tca13298-sec-0010}
------------------------------------------------

The STRING database (<http://string-db.org/>) provides a significant association of protein‐protein interactions (PPIs).[14](#tca13298-bib-0014){ref-type="ref"} Cytoscape is used for the visual exploration of interaction networks.[15](#tca13298-bib-0015){ref-type="ref"} In this study, DEG PPI networks were analyzed by the STRING database and subsequently visualized by using Cytoscape. The cutoff criterion was set as a combined score \>0.4. The Cytoscape plugin CytoHubba[16](#tca13298-bib-0016){ref-type="ref"} was used to identify the hub genes by finding the intersection of the top 30 genes from 12 topological analysis methods. Molecular Complex Detection (MCODE) was then used to screen out modules of PPI networks, and the degree cutoff = 2, node score cutoff = 0.2, k‐core = 2, and max depth = 100.[17](#tca13298-bib-0017){ref-type="ref"}

Hub gene validation by GEPIA {#tca13298-sec-0011}
----------------------------

The Gene Expression Profiling Interactive Analysis (GEPIA) database (<http://gepia.cancer-pku.cn/>) is a web‐based tool to deliver fast and customizable functionalities based on The Cancer Genome Atlas (TCGA) and Genotype‐Tissue Expression (GTEx) data.[18](#tca13298-bib-0018){ref-type="ref"} In this study, the GEPIA database was used to validate the expression of hub genes identified in the module, and analyze the association of their expression levels with NSCLC TNM stage. We selected *P* \< 0.05 and fold change \>2 as a threshold.

Exploring cancer genomics data by cBioportal {#tca13298-sec-0012}
--------------------------------------------

The cBioPortal for Cancer Genomics (<http://cbioportal.org>) provides a resource for visualization and analyzing multidimensional cancer genomics data.[19](#tca13298-bib-0019){ref-type="ref"} In this study, alteration frequencies of hub genes were performed based on mutation and DNA copy‐number alterations in four selected lung cancer subtypes: Lung Adenocarcinoma‐TCGA, Provisional; Pan‐Lung Cancer‐TCGA, Nat Genet 2016; Small‐Cell Lung Cancer, U Cologne, Nature 2015; Lung Squamous Cell Carcinoma‐TCGA, Provisional.

Survival analysis of hub genes {#tca13298-sec-0013}
------------------------------

A Kaplan‐Meier plotter (<http://www.kmplot.com>) was used to assess the effect of 54 675 genes on survival using 10 461 samples including 5143 breast, 1816 ovarian, 2437 lung, and 1065 gastric cancer patients.[20](#tca13298-bib-0020){ref-type="ref"} The relapse‐free and overall survival (OS) information was based on the GEO, EGA and TCGA database. The hazard ratio (HR) with 95% confidence intervals and log rank *P*‐value were calculated and indicated on the plot.[21](#tca13298-bib-0021){ref-type="ref"}

Cell culture {#tca13298-sec-0014}
------------

The human lung adenocarcinoma H2935, H4006 cells and lung squamous cell carcinoma H226 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human bronchial epithelial BEAS‐2B cells were purchased from MssBio Co., Ltd. (Guangzhou, China). H2935, H4006, H226 and BEAS‐2B cells were cultured at Roswell Park Memorial Institute (RPMI); 1640 medium (GIBCO, Los Angeles, CA, USA), which contained 10% fetal bovine serum (FBS) and 100 U/mL penicillin‐streptomycin sulfate. All cell lines were grown in a humidified incubator at 37°C (5% CO2) environment.

Detection of hub gene expression level {#tca13298-sec-0015}
--------------------------------------

Total RNA was extracted from the cells using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). Single‐strand cDNA was synthesized from 1 mg of total RNA using the PrimeScript RT reagent Kit with gDNA Eraser (Takara Biotechnology Co. Ltd., Dalian, China). Reverse transcription quantitative PCR was used to detect the expression of mRNA of hub genes by 7500 PCR system (Thermo Fisher Scientific). The primers were as follows in the Table [1](#tca13298-tbl-0001){ref-type="table"}. The following cycling conditions: 95 minutes or five minutes, followed by 40 cycles of 95°C for 20 seconds and 60°C for 30 seconds. qPCR assays were conducted in triplicate in a 10 mL reaction volume each sample. And calculate the relative expression of *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* mRNA by 2‐Ct method.

###### 

The primer of hub genes

  Primer name   Sense                    Antisense
  ------------- ------------------------ ------------------------
  *AURKA*       CATTCCTTTGCAAGCACAAAAG   ATTTCAAAGTCTTCCAAAGCCC
  *KIAA0101*    AGGTTGTCCCCTAAAGATTCTG   ATCATTTGTGTGATCAGGTTGC
  *CDC20*       AGCAGCAGATGAGACCCTGAGG   CAGCGGATGCCTTGGTGGATG
  *MKI67*       CAGACATCAGGAGAGACTACAC   GTTAGACTTGCTGCTGAGTCTA
  *CHEK1*       CTCAAGTTTTGGCGGGAAAAG    AAGTTGAACTTCTCCATAGGCA
  *HJURP*       AAAGACCCAGGCTATCAGAAC    TGTTCTCTCCTCTCTCTTCTGA
  *OIP5*        GTGGTCTTCTCCAGAGTTACAA   GAATACAGATGGAAACCAACGG

Analysis of hub gene expression in the Oncomine database {#tca13298-sec-0016}
--------------------------------------------------------

The Oncomine database (<http://www.oncomine.org>) was applied for differential expression classification of common cancer types, and their respective normal tissues, as well as clinical and pathological analyses. In this study, the Oncomine database was used to further analyze the expression of hub genes in other lung adenocarcinoma datasets.

Results {#tca13298-sec-0017}
=======

Identification of DEGs {#tca13298-sec-0018}
----------------------

A total of 49 upregulated and 72 downregulated DEGs were identified from four datasets. The DEGs at the intersection of the four databases were selected for further investigation by Venn\'s diagram (Table [2](#tca13298-tbl-0002){ref-type="table"} and Fig [1a](#tca13298-fig-0001){ref-type="fig"}--[c](#tca13298-fig-0001){ref-type="fig"}).

###### 

The gene expression profile data characteristics

  Record     Tissue   Platform                                                                             Normal   Tumor   Reference
  ---------- -------- ------------------------------------------------------------------------------------ -------- ------- ------------------------------------------------------------------
  GSE18842   NSCLC    GPL570\[HG‐U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                 45       46      Sanchez‐Palencia *et al*.[5](#tca13298-bib-0005){ref-type="ref"}
  GSE33532   NSCLC    GPL570\[HG‐U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                 20       80      Meister *et al*.[6](#tca13298-bib-0006){ref-type="ref"}
  GSE62113   NSCLC    GPL14951Illumina HumanHT‐12 WG‐DASL V4.0 R2 expression beadchip                      9        10      Li *et al*.[7](#tca13298-bib-0007){ref-type="ref"}
  GSE74706   NSCLC    GPL13497Agilent‐026652 Whole Human Genome Microarray 4x44K v2 (Probe Name version)   18       18      Marwitz *et al*.[8](#tca13298-bib-0008){ref-type="ref"}

![Identification of DEGs in profiling datasets. (**a**) Venn\'s diagram of upregulated DEGs; (**b**) Venn\'s diagram of downregulated DEGs; (**c**) Heatmap plot of the DEGs in the GSE33532 dataset. Red, higher expression; green, lower expression.](TCA-11-851-g001){#tca13298-fig-0001}

Enrichment analyses {#tca13298-sec-0019}
-------------------

To further understand the function and mechanism of the identified DEGs, GO and KEGG enrichment analyses were performed using the ClusterProfiler package. The upregulated DEGs were mainly associated with the BP terms mitotic nuclear division, nuclear division, organelle fission, chromosome segregation and regulation of cell cycle phase transition (Fig [2a](#tca13298-fig-0002){ref-type="fig"}). Additionally, CC analysis showed that the upregulated genes were associated with spindle, chromosomal region, midbody and centrosome, and the downregulated genes were mainly found in apical part of cell, apical plasma membrane, cell projection membrane, lamellar body and multivesicular body (Figs [2b](#tca13298-fig-0002){ref-type="fig"} and [3a](#tca13298-fig-0003){ref-type="fig"}). Moreover, for upregulated genes, MF terms were mainly protein serine/threonine kinase activity, protein serine/threonine/tyrosine kinase activity, kinetochore binding and histone kinase activity (Fig [2c](#tca13298-fig-0002){ref-type="fig"}).

![Functional and pathway enrichment analysis of upregulated genes. (**a**) Enrichment of biological process. (**b**) Enrichment of cellular component. (**c**) Enrichment of molecular function. (**d**) Enrichment of Kyoto Encyclopedia of Genes and Genomes. The y‐axis shows significantly enriched pathways, and the x‐axis shows the Rich factor. Rich factor stands for the ratio of the number of target genes belonging to a pathway to the number of all the annotated genes located in the pathway. The higher Rich factor represents the higher level of enrichment. The size of the dot indicates the number of target genes in the pathway, and the color of the dot reflects the different *P*‐value range.](TCA-11-851-g002){#tca13298-fig-0002}

![Functional and pathway enrichment analysis of downregulated genes. (**a**) Enrichment of cellular component. (**b**) Enrichment of Kyoto Encyclopedia of Genes and Genomes.](TCA-11-851-g003){#tca13298-fig-0003}

The main three pathways that were particularly enriched by upregulated DEGs were P53 signaling pathway, cell cycle and cellular senescence (Fig [2d](#tca13298-fig-0002){ref-type="fig"}). Similarly, downregulated DEGs were notably enriched in ECM‐receptor interaction, AGE‐RAGE signaling pathway in diabetic complications, hypertrophic cardiomyopathy and dilated cardiomyopathy (Fig [3b](#tca13298-fig-0003){ref-type="fig"}).

PPI network construction {#tca13298-sec-0020}
------------------------

The DEG PPI network consisted of 121 nodes and 588 edges, including 49 upregulated genes and 72 downregulated genes (Fig [4a](#tca13298-fig-0004){ref-type="fig"}). A total of 10 hub genes were selected by the CytoHubba, including CLDN5, CHEK1, MKI67, *AURKA*, *KIAA0101*, *HJURP*, *CDC20*, *OIP5*, *C4BPA* and *CA4*. A significant module was obtained from the DEG PPI network by using MCODE, including 33 nodes and 523 edges (Fig [4b](#tca13298-fig-0004){ref-type="fig"}). Functional and KEGG pathway enrichment analyses revealed that genes in this module were mainly associated with cell cycle, p53 signaling pathway and cellular senescence (Fig [5a](#tca13298-fig-0005){ref-type="fig"}--[d](#tca13298-fig-0005){ref-type="fig"}). Furthermore, we found that *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* were involved in the GO, KEGG, and module analyses (Table [3](#tca13298-tbl-0003){ref-type="table"}).

![PPI network and module analysis. (**a**) PPI network of DEGs. (**b**) A significant module selected from PPI network. Red nodes, upregulated genes; yellow nodes, downregulated genes; red lines, strong interaction relationship between nodes; green lines, weak interaction relationship between nodes.](TCA-11-851-g004){#tca13298-fig-0004}

![Functional and pathway enrichment analysis of module. (**a**) Enrichment of biological process. (**b**) Enrichment of cellular component. (**c**) Enrichment of molecular function. (**d**) Enrichment of Kyoto Encyclopedia of Genes and Genomes.](TCA-11-851-g005){#tca13298-fig-0005}

###### 

Hub genes with high degree of connectivity

  Gene         Degree   Type   MCODE cluster
  ------------ -------- ------ ---------------
  *AURKA*      34       up     Cluster 1
  *KIAA0101*   33       up     Cluster 1
  *CDC20*      33       up     Cluster 1
  *MKI67*      33       up     Cluster 1
  *CHEK1*      33       up     Cluster 1
  *HJURP*      32       up     Cluster 1
  *OIP5*       31       up     Cluster 1

Hub gene validation {#tca13298-sec-0021}
-------------------

GEPIA, the online tool with data sourced from TCGA and GTEx, was used to validate the expression of these hub genes in lung cancer. GEPIA provides box plots, violin plots based on pathological stages, dot plots, and matrix plots. Consistent with the GEO analysis, GEPIA box plots of key gene expression levels showed that seven hub genes were overexpressed in lung cancer samples compared with normal tissues (Fig [6a](#tca13298-fig-0006){ref-type="fig"}--[g](#tca13298-fig-0006){ref-type="fig"}). In addition, GEPIA violin plots of gene expression by pathological stages based on the TCGA clinical annotation revealed their high expression levels significantly associated with advanced TNM stage (*P*‐value \<0.05) (Fig [7a](#tca13298-fig-0007){ref-type="fig"}--[g](#tca13298-fig-0007){ref-type="fig"}).

![The expression level of hub genes in NSCLC. (**a**) *AURKA*; (**b**) *CDC20*; (**c**) *CHEK1*; (**d**) *HJURP*; (**e**) *KIAA0101*; (**f**) *MKI67* and (**g**) *OIP5*. The red and gray boxes represent cancer and normal tissues, respectively. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](TCA-11-851-g006){#tca13298-fig-0006}

![Violin plots of hub genes in NSCLC. (**a**) *AURKA*; (**b**) *CDC20*; (**c**) *CHEK1*; (**d**) *HJURP*; (**e**) *KIAA0101*; (**f**) *MKI67* and (**g**) *OIP5*.](TCA-11-851-g007){#tca13298-fig-0007}

Genomic alterations of hub genes {#tca13298-sec-0022}
--------------------------------

We explored the specific alterations of hub genes using the cBioportal tool in four selected lung cancer datasets with 1662 samples. Cancer type summary analysis showed that the ratio of alteration of seven genes varied from 11.46% to 17.5%, with the lowest to highest level as lung squamous cell carcinoma, small‐cell lung cancer, and LAC in four lung cancer datasets (Fig [8a](#tca13298-fig-0008){ref-type="fig"}--[h](#tca13298-fig-0008){ref-type="fig"}).

![Matrix heatmap of hub genes in four selected lung datasets. (**a**) All hub genes; (**b**) *AURKA*; (**c**) *CDC20*; (**d**) *CHEK1*; (**e**) *HJURP*; (**f**) *KIAA0101*; (**g**) *MKI67* and (**h**) *OIP5*. Each row represents a gene and each column a tumor sample. Red bars, gene amplifications. Blue bars, deep deletion. Green squares, missense mutation.](TCA-11-851-g008){#tca13298-fig-0008}

Overall survival analyses {#tca13298-sec-0023}
-------------------------

Overall survival analysis of hub genes was performed using the Kaplan‐Meier plotter. It was found that high expression of *AURKA* (HR 1.52 \[1.33--1.72\], log‐rank *P* = 1.2e--10), *CDC20* (HR 1.82 \[1.6--2.07\], log‐rank *P* \< 1e--16), *CHEK1* (HR 1.9 \[1.6--2.25\], log‐rank *P* = 3.2e--14), *HJURP* (HR 1.89 \[1.66--2.15\], log‐rank *P* \< 1e--16), *KIAA0101* (HR 1.56 \[1.37--1.77\], log‐rank *P* \< 5.1e--12), *MKI67* (HR 1.6 \[1.41--1.82\], log‐rank *P* \< 2.6e--13), and *OIP5* (HR 1.79 \[1.57--2.03\], log‐rank *P* = 1e--16) was associated with worse OS for lung cancer patients (Fig [9a](#tca13298-fig-0009){ref-type="fig"}--[g](#tca13298-fig-0009){ref-type="fig"}).

![Prognostic value of hub genes in lung cancer patients. (**a**) *OIP5*; (**b**) *MKI67*; (**c**) *KIAA0101*; (**d**) *HJURP*; (**e**) *CHEK1*; (**f**) *CDC20* and (**g**) *AURKA*.](TCA-11-851-g009){#tca13298-fig-0009}

Gene expression levels of seven genes in lung cancer cells {#tca13298-sec-0024}
----------------------------------------------------------

The RT‐qPCR results showed that the gene expression level of *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* in H2935, H4006 and H226 cell lines was significantly higher than BEAS‐2B cells lines. Finally, we analyzed the expression of *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* in lung adenocarcinoma using the Oncomine database, and the results showed that hub genes were upregulated in lung cancer tissues and downregulated in normal tissues (Fig [10a](#tca13298-fig-0010){ref-type="fig"}--[n](#tca13298-fig-0010){ref-type="fig"}).

![Histogram of the difference between expression of hub genes in lung cancer cells and the Oncomine database. (**a**,**b**) *AURKA*; (**c**,**d**) *CDC20*; (**e**,**f**) *CHEK1*; (**g**,**h**) *HJURP*; (**i**,**j**) *KIAA0101*; (**k**,**l**) *MKI67* and (**m**,**n**) *OIP5*. \*\*Compared to normal groups, *P* \< 0.05, \*\*\**P* \< 0.001. \*\*\*\**P \<* 0.0001.](TCA-11-851-g010){#tca13298-fig-0010}

Discussion {#tca13298-sec-0025}
==========

In this study, we performed a series of bioinformatics analysis to screen key genes and pathways. The expression profiles found that 49 upregulated genes and 72 downregulated genes overlap DEGs (Intersection area of each dataset) were identified in lung cancer tissues compared to adjacent lung tissues. The upregulated genes were mainly enriched in P53 signaling pathway, cell cycle and cellular senescence, and closely related to tumorigenesis or metastasis. The downregulated genes were mainly enriched in ECM‐receptor interaction, AGE‐RAGE signaling pathway in diabetic complications, hypertrophic cardiomyopathy and dilated cardiomyopathy. Among the DEGs, the top 10 hub genes selected in the PPI network were all overexpressed. Functional and pathway enrichment analyses revealed that the significant modules were mainly enriched in cell cycle, p53 signaling pathway and cellular senescence.

Based on these findings, DEGs including *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* were identified in these functions. These genes were also hub nodes in PPI networks. We then found the expression of seven key genes in NSCLC were higher than the control group. Furthermore, we researched the genomic alterations of hub genes in lung cancer cases from TCGA databases using the cBioPortal tool. We found hub gene mutation frequencies were highest in LUAD. Compared with other hub genes in lung cancer samples, *MKI67* and *CHEK1* had a higher alteration frequency of 6% and 2.7%, respectively. Survival analysis of the seven key genes showed that these genes were significantly associated with lung cancer.

Our bioinformatics analysis results predicted that *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* gene markers may be closely related to the development of NSCLC. Finally, the verification results in cells showed that the expression of the hub genes was higher in lung cancer cells than normal cells, indicating that seven genes may play a significant role in the occurrence and development of lung cancer.

Aurora kinase A (*AURKA*) is a protein coding gene which plays a critical role in regulating many of the processes that are pivotal to mitosis. *AURKA* has many functions including regulation of cell cycle progression and the p53 /TP53 pathway.[22](#tca13298-bib-0022){ref-type="ref"} This gene may play a role in tumor development and progression. Diseases associated with *AURKA* include breast, colorectal, gastric, and liver cancers.[23](#tca13298-bib-0023){ref-type="ref"}, [24](#tca13298-bib-0024){ref-type="ref"}, [25](#tca13298-bib-0025){ref-type="ref"}, [26](#tca13298-bib-0026){ref-type="ref"} Previous studies have confirmed that *AURKA* expression is associated with lung cancer progression. A study by Zheng *et al*. showed that *AURKA*‐mediated phosphorylation of LKB1 may compromise the LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.[27](#tca13298-bib-0027){ref-type="ref"} Additionally, Schneider *et al*.[28](#tca13298-bib-0028){ref-type="ref"} demonstrated that that the expression of the mitosis‐associated genes *AURKA* is associated with the prognosis of NSCLC patients. Therefore, our results suggest that *AURKA* may play an important role in future diagnostic and therapeutic targets in the treatment of lung cancer.

PCNA Clamp Associated Factor (PCLAF/*KIAA0101*) is a 15‐kDa protein containing a conserved proliferating cell nuclear antigen (PCNA)‐binding motif, a key factor in DNA repair and/or apoptosis and cell cycle regulation, which has been observed in a variety of human malignancies.[29](#tca13298-bib-0029){ref-type="ref"} The functions of *KIAA0101* mainly include cellular response to DNA damage stimulus, DNA replication and, regulation of cell cycle.[30](#tca13298-bib-0030){ref-type="ref"}, [31](#tca13298-bib-0031){ref-type="ref"}, [32](#tca13298-bib-0032){ref-type="ref"} Several studies have revealed that *KIAA0101* overexpression is associated with the progression and recurrence in prostate cancer, gastric cancer, breast cancer, liver cancer and other malignancies.[33](#tca13298-bib-0033){ref-type="ref"}, [34](#tca13298-bib-0034){ref-type="ref"}, [35](#tca13298-bib-0035){ref-type="ref"}, [36](#tca13298-bib-0036){ref-type="ref"} A study showed that *KIAA0101* overexpression was an independent prognostic factor, and associated with high‐grade tumor, high‐stage tumor, and early tumor recurrence in hepatocellular carcinoma.[36](#tca13298-bib-0036){ref-type="ref"} However, there is insufficient evidence to support the role of *KIAA0101* in lung cancer. Kato *et al*. reported that overexpression of *KIAA0101* may predict a poor prognosis in primary lung cancer patients.[29](#tca13298-bib-0029){ref-type="ref"} Cell cycle regulatory factors play an important role in cancer development, and this study suggested that *KIAA0101* may be a cell cycle regulatory factor with therapeutic potential for the treatment of lung cancer.

Cell division cycle 20 (*CDC20*) is an important spindle assembly checkpoint protein and activates APC/C to initiate anaphase.[37](#tca13298-bib-0037){ref-type="ref"}, [38](#tca13298-bib-0038){ref-type="ref"} Previous studies have already reported overexpression of *CDC20* in various tumors such as gastric, breast, prostate, colorectal tumors and others.[39](#tca13298-bib-0039){ref-type="ref"}, [40](#tca13298-bib-0040){ref-type="ref"}, [41](#tca13298-bib-0041){ref-type="ref"}, [42](#tca13298-bib-0042){ref-type="ref"} Currently, the overexpression of *CDC20* has been reported in human NSCLC[43](#tca13298-bib-0043){ref-type="ref"} and the overexpression of *CDC20* has been shown to predict a poor prognosis in primary NSCLC patients.[44](#tca13298-bib-0044){ref-type="ref"} In our study, we found that *CDC20* was enriched in cell cycle pathway and oocyte meiosis, and involved in the GO BP terms cell cycle phase, M phase, mitotic cell cycle and nuclear division. Cell cycle dysregulation underlies the aberrant cell proliferation which characterizes cancer, and the loss of cell cycle checkpoint control promotes genetic instability. *CDC20* was highly expressed in NSCLC samples compared with normal samples in our study. Thus, our findings suggest that *CDC20* may be a promising diagnostic and therapeutic target in NSCLC.

Marker of proliferation Ki‐67 (*MKI67*) is a protein coding gene which is expressed in proliferating cells. Due to being strongly expressed in proliferating cells, the *MKI67* has been considered as an established prognostic indicator for the assessment of cell proliferation in biopsies from cancer patients.[45](#tca13298-bib-0045){ref-type="ref"}, [46](#tca13298-bib-0046){ref-type="ref"} Ki‐67 is primarily expressed during the active phases of the cell cycle, cell population proliferation, regulation of mitotic nuclear division and regulation of mitotic nuclear division.[47](#tca13298-bib-0047){ref-type="ref"}, [48](#tca13298-bib-0048){ref-type="ref"} Accumulating evidence has shown that *MKI67* overexpression is associated with cancer progression and prognosis in prostate cancer, breast cancer, gastric cancer and nasopharyngeal carcinoma.[49](#tca13298-bib-0049){ref-type="ref"}, [50](#tca13298-bib-0050){ref-type="ref"}, [51](#tca13298-bib-0051){ref-type="ref"}, [52](#tca13298-bib-0052){ref-type="ref"} A study reported that E‐cadherin and Ki‐67 together play a key role in the development, invasion and metastasis of NSCLC.[53](#tca13298-bib-0053){ref-type="ref"} Our results further revealed that *MKI67* might play an important role in lung cancer development and could be used as a therapeutic target for NSCLC cancer patients.

Checkpoint kinase 1 (*CHEK1*) encodes serine/threonine kinases which is a central component of DNA damage response and is involved in the control of the cell cycle. The function of *CHEK1* is to regulate cell cycle checkpoints, and coordinate cellular activities involving DNA repair and cell cycle arrest.[54](#tca13298-bib-0054){ref-type="ref"} More and more research has indicated that *CHEK1* is widely associated with carcinoma, such as breast, ovarian and colorectal cancers.[55](#tca13298-bib-0055){ref-type="ref"}, [56](#tca13298-bib-0056){ref-type="ref"}, [57](#tca13298-bib-0057){ref-type="ref"} There is a lack of evidence in determining the relationship between *CHEK1* and NSCLC, with a study by Liu *et al*. reporting that miR‐195 interacted with *CHEK1* mRNA and suppressed its protein expression in NSCLC, indicating that *CHEK1* expression may be associated with patient survival.[58](#tca13298-bib-0058){ref-type="ref"} Our results demonstrated that *CHEK1* might contribute to NSCLC and be used as a novel therapeutic target in NSCLC.

The Holliday junction recognition protein (*HJURP*) is an exclusive companion for the centromere CENP‐A deposition during the early G1 phase.[59](#tca13298-bib-0059){ref-type="ref"} In the human being, *HJURP* has been identified to be an important regulator of DNA binding and phosphorylation involved in the regulation of chromosomal segregation and cell division.[60](#tca13298-bib-0060){ref-type="ref"}, [61](#tca13298-bib-0061){ref-type="ref"} Recently, the biological effects of *HJURP* attracted growing attention in several tumors such as hepatocellular carcinoma, breast cancer, and glioblastoma.[62](#tca13298-bib-0062){ref-type="ref"}, [63](#tca13298-bib-0063){ref-type="ref"}, [64](#tca13298-bib-0064){ref-type="ref"} A study by Zhou *et al*. reported that *HJURP* was found to be overexpressed in lung cancer[65](#tca13298-bib-0065){ref-type="ref"} and promoted NSCLC cell proliferation and metastasis by inactivating the Wnt/β‐catenin pathway in the report by Wei *et al*.[66](#tca13298-bib-0066){ref-type="ref"} Our observations suggest that *HJURP* abnormalities may contribute to the risk of developing lung cancer.

Opa Interacting Protein 5 (*OIP5*) is a protein coding gene. The protein encoded by this gene localizes to centromeres where it is essential for recruitment of CENP‐A through the mediator Holliday junction recognition protein.[67](#tca13298-bib-0067){ref-type="ref"} Expression of this gene is upregulated in several cancers including bladder cancer, gastric cancer, colorectal cancer, breast cancer and hepatocellular carcinoma.[68](#tca13298-bib-0068){ref-type="ref"}, [69](#tca13298-bib-0069){ref-type="ref"}, [70](#tca13298-bib-0070){ref-type="ref"}, [71](#tca13298-bib-0071){ref-type="ref"} In lung cancer, *OIP5* might play an important role in the growth of lung cancers by interacting with Raf1.[72](#tca13298-bib-0072){ref-type="ref"} Furthermore, in our study, we were able to demonstrate that *OIP5* was a key gene in tumor development in NSCLC.

Compared with previous work, our study has several advantages. First, this study had a large sample size obtained from multiple GEO datasets. Second, we further analyzed and visualized the functional and pathway enrichment of the main DEGs. Third, the hub genes were cross‐validated using different databases such as GEO, TCGA, Oncomine and GTEx. Finally, we determined the expression level of hub genes in different cell lines by quantitative reverse transcription PCR.

However, there are some limitations to our study. First, the quality of data from the GEO database could not be appraised. Second, our results did not include characteristics such as sex, age, smoke, tumor classification, and staging in detail. We are therefore of the opinion that there should be more clinical research in order to confirm our results.

In conclusion, in this study, we determined that *AURKA*, *KIAA0101*, *CDC20*, *MKI67*, *CHEK1*, *HJURP* and *OIP5* may be critical genes in the development and prognosis of lung cancer through bioinformatics analysis combined with quantitative reverse transcription PCR. However, it is essential that further experiments are carried out and clinical data made available to confirm the results of our study and guide the discovery of future gene therapies against NSCLC.
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